APOLIPOPROTEIN-E POLYMORPHISM AND CORONARY-ARTERY DISEASE

APOLIPOPROTEIN-E POLYMORPHISM AND CORONARY-ARTERY DISEASE
复制标题

DOI:
10.1161/01.atv.3.4.310
复制
发表时间:
1983-01-01
期刊:
ARTERIOSCLEROSIS
影响因子:
--
通讯作者:
ASSMANN, G
ASSMANN, G
中科院分区:
其他
文献类型:
--
作者:
MENZEL, HJ;KLADETZKY, RG;ASSMANN, G

文献摘要

被引文献

相似文献

在1000名接受冠状动脉造影的患者中检测了脂质状态和载脂蛋白E表型。同样数量的工厂员工被选为对照组。我们区分了六种不同的载脂蛋白E表型,并确定了它们在所有组中的频率。纯合型E3/3、E4/4和E2/2在工厂职工群体中的分布比例分别为62.7%、2.3%和0.8%;杂合型E4/3、E3/2和E4/2的频率分别为20.3%、11.0%和3.0%。在有和无冠状动脉硬化征象的患者组中,除了杂合(E3/2)在未受冠状动脉硬化影响的冠状动脉造影患者组中发生的频率明显更高外,观察到的频率几乎相同。冠状动脉疾病患者的胆固醇和甘油三酯值显著升高,而高密度脂蛋白胆固醇水平无显著差异。显然,载脂蛋白E2/2的纯合性,尽管存在。-这些患者血浆中的低密度脂蛋白不能被认为是冠状动脉粥样硬化风险增加的生化指标。另一方面,载脂蛋白E3/2杂合性可能对早期动脉粥样硬化的发生发展具有保护作用。
Lipid status and apolipoprotein E phenotypes were tested in 1000 patients who underwent coronary angiography. The same number of factory employees was chosen as a control group. Six different apolipoprotein E phenotypes were distinguished and their frequencies in all groups were determined. For the 3 homozygous phenotypes, E3/3, E4/4 and E2/2, the percentage distribution in the group of factory employees was 62.7, 2.3 and 0.8%, respectively; for the 3 heterozygous phenotypes, E4/3, E3/2 and E4/2, frequencies of 20.3, 11.0 and 3.0% were determined. In the group of patients with and without signs of coronary arterosclerosis almost the same frequencies were observed except that heterozygous (E3/2) occurred significantly more frequently in the group of coronary angiography patients unaffected by coronary sclerosis. Cholesterol and triglyceride values were significantly elevated in patients with coronary artery disease, whereas high density lipoprotein cholesterol levels were not significantly different. Apparently, apolipoprotein E2/2 homozygosity, despite the presence of .beta.-very low density lipoproteins in the plasma of these patients, cannot be considered a biochemical indicator of an increased risk of coronary atherosclerosis. On the other hand, apolipoprotein E3/2 heterozygosity may have a protective effect on the development of early atherosclerosis.